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Endoscopic ultrasound (EUS) has assumed an increasing role in the management of pancreaticobiliary
disease over the past 2 decades but its impact is particularly evident in the management of pancreatic
masses. EUS helps improve patients′ outcomes by enhancing tumor detection and staging while
providing safe and reliable tissue diagnosis. This review provides an evidence-based approach to the
use of EUS for the diagnosis of pancreatic cancer, its staging, and for the determination of resectability
compared to other imaging modalities. We will focus on techniques specific to obtaining tissue from
solid pancreatic masses and will review best practices in EUS-guided tissue acquisition.
& 2018 Elsevier Inc. All rights reserved.67
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831. Introduction
Advancements in radiologic and endoscopic ultrasound (EUS) 
imaging have improved our ability to detect and stage pancreatic
masses allowing for more selective surgical intervention for
patients with “resectable disease.” Owing to the low sensitivity
of cross-sectional imaging to detect small tumors in the pancreas,
endoscopic diagnosis by using EUS has become a mainstay for the
assessment of pancreatic masses. EUS also provides a reliable
method for tissue sampling hence securing a histopathologic
diagnosis [1-3]. This review will focus on the role of EUS in the
evaluation of pancreatic masses compared to other imaging
modalities, and highlights the best practices to improve tissue
yield from EUS-guided tissue acquisition (EUS-TA).84
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972. Pancreatic cancer
2.1. Background and epidemiology
Pancreatic cancer is the fourth leading cause of cancer-related
mortality in the United States. Over 45,000 patients are diagnosed
each year in the United States, and the majority of these patients
succumb to their disease [4]. Eighty percentage of patients are
diagnosed with advanced, unresectable disease. According to the
latest statistics, only 7% of patients survive 5 years after diagnosis
[4]. While the 5-year survival rate improves to 25% in patients
presenting with stage 1 or localized disease, only 9% of patients are98
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ided tissue acquisition of panidentified at this early stage. The majority of patients (53%)
presents with distant, metastatic disease, and have a 5-year
survival of 2%. Identification of risk factors and establishing earlier
detection methods are therefore of paramount importance [5].
2.2. Cross-sectional imaging
2.2.1. Computed tomography
Computed tomography (CT) is the most widely used imaging
modality for the assessment of suspected pancreatic ductal
adenocarcinoma (PDAC). CT imaging has significantly improved
with the introduction of multiple-detector CT (MDCT), which
allows high-resolution and multiplanar image reconstruction. CT
is reported to have a sensitivity of 89%-97% for PDAC, though it is
less effective in diagnosing small (o 2 cm) lesions with a
sensitivity of 65%-75% [6]. In this respect, EUS is superior in tumor
detection. Comparative studies between EUS and MDCT for pan-
creatic tumors have demonstrated the superiority of EUS for tumor
detection compared to multirow CT. Agarwal et al [7] reported an
EUS sensitivity of 100% for the diagnosis of cancer compared to
86% for MDCT. Similarly, DeWitt et al [8] reported that the
sensitivity of EUS (98%) was statistically superior to MDCT (86%)
in a cohort of 80 patients with pancreatic cancer.
2.2.2. Magnetic resonance imaging
Contrast-enhanced magnetic resonance imaging (MRI) has a
sensitivity and accuracy at least similar to that of MDCT for
diagnosis and staging of pancreatic cancer, but it is costlier and
less readily available than MDCT. MRI, however, may more reliably
detect smaller, non–contour-deforming tumors compared with CT
[9]. MRI also more accurately detects and characterizes smaller
hepatic metastases [10]. A recent study concluded that MRI was102
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evaluation of resectability [11]. In a study that compared the
diagnostic performance (detection, local staging) of multiphasic
64-detector CT with gadobenate dimeglumine-enhanced 3.0-T
MRI in patients suspected of having pancreatic cancer, both CT
and MRI were found to be equally suited for detecting and staging
pancreatic cancer [12]. Therefore, the choice of imaging modality
for detection and staging of pancreatic cancer depends on test
availability and local expertise.180
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Fig. 1. A linear EUS image of a small liver lesion not visualized on CT scan in a
patient undergoing staging and FNA of a pancreatic body mass. Cytology from the
lesion confirmed metastatic pancreatic adenocarcinoma. (Color version of figure is
available online.)
Fig. 2. A linear EUS image of a pancreatic head mass invading the portovenous
confluence. This patient underwent neoadjuvant therapy to downstage the tumor
followed by pancreaticoduodenectomy with venous reconstruction.2.2.3. Positron emission tomography and integrated PET/CT
The role of functional imaging especially positron emission
tomography with 2-deoxy-2-[fluorine-18]fluoro-D-glucose inte-
grated with CT (FDG-PET/CT) is still uncertain in the staging of
pancreas cancer. The NCCN guidelines list the possible perform-
ance of PET/CT for the detection of regional lymph nodes and
extrapancreatic metastases, although it has not been incorporated
in routine practice [13]. The sensitivity and specificity of FDG-PET/
CT in the diagnosis and evaluation of pancreas cancer ranges from
71%-100% and 64%-95%, respectively, significantly higher than
those of CT alone [14,15]. The sensitivity of PET/contrast-enhanced
CT in detecting local recurrence, abdominal lymph node meta-
stasis, and peritoneal dissemination are 83%, 88%, and 83%,
respectively [16]. A meta-analysis of 51 studies involving 3857
patients compared the diagnostic performance of 18FDG PET alone,
18FDG PET/CT, and EUS for diagnosing pancreatic cancer [17]. The
study concluded that the pooled sensitivity for combined PET/CT
(90.1%) was significantly higher than PET (88%) and EUS (81%).
However, the pooled specificity estimate for EUS (93.2%) was
significantly higher than PET (83%) and PET/CT (80%).
2.3. Staging of pancreatic adenocarcinoma
Staging of pancreatic cancer is performed according to the
American Joint Committee for Cancer (AJCC) Staging TNM classi-
fication, which describes the tumor extension (T), lymph node (N),
and distant metastases (M) of tumors, respectively [18]. The
accuracy of EUS for T staging of pancreatic tumors ranges from
62%-94% [19-21]; while its accuracy for N staging ranges from
41%-86% [5].
Para-aortic lymph nodes (PALNs) are considered nonregional
lymph nodes for both pancreatic head and body or tail cancers,
us meticulous survey of this region is critical during staging of all
pancreatic tumors [22]. Kurita et al [23] conducted a prospective,
nonrandomized single-center trial, of 208 patients with pancrea-
tobiliary cancers without apparent distant metastases except for
PALNs. PET/CT and EUS-guided fine-needle aspiration (EUS-FNA)
were performed sequentially as a single combined procedure to
valuate PALN metastasis. EUS-FNA had higher sensitivity, specif-
icity, positive predictive value, negative predictive value, and
accuracy for the diagnosis of PALNs metastasis than PET/CT. The
differences for the sensitivity and accuracy were significant (P o
0.001). An EUS survey of mediastinal stations for metastatic
adenopathy is also warranted since these are also considered
nonregional lymph nodes.
For detection of nonnodal metastatic cancer, CT and MRI are
superior to EUS due to both anatomical considerations of the
upper gastrointestinal tract and the limited range of EUS imaging.
However, EUS still has an important role in the evaluation of
hepatic metastasis in the left or caudate lobe (Figure 1) and
malignant ascites, some of which can be missed on cross-sectional
imaging and both of which can be accessible by EUS-FNA.
Identification of liver metastases or malignant ascites by EUS-
FNA may preclude surgical resection and is associated with poor
survival following diagnosis [24].2.4. Assessment of vascular invasion
The overall accuracy of EUS for vascular invasion ranges from
68%-93% [19,25-27]. The overall accuracy of CT is reportedly
equivalent [19,26] or inferior [25] to EUS. The overall accuracy of
MRI is reportedly equivalent [19] or superior [26] to EUS.
The overall sensitivity and specificity of EUS for malignant
vascular invasion range from 42%-91% and 89%-100%, respectively
[19,25-27]. The sensitivity of EUS for tumor invasion of the PV or
porto-splenic confluence is 60%-100% [28,29] with most studies
demonstrating sensitivities over 80%. The sensitivity of EUS for PV
invasion (Figure 2) is consistently superior to that of CT [28,30,31].
For the superior mesenteric vein, superior mesenteric artery
(Video 1), and celiac artery, the sensitivity of EUS is 17%-83%
[27], 17% [32], and about 50% [28], respectively. The sensitivity of
CT for staging of the superior mesenteric artery [31,32] and celiac
artery [28] appears to be better than EUS. Until further conclusive
data becomes available, assessment of tumor resectability should
be done by both EUS and CT (or MRI) rather than by EUS alone.
2.5. Resectability of pancreatic tumors
In a pooled analysis of 9 studies involving 377 patients, the
sensitivity and specificity of EUS for resectability of pancreatic
cancer was 69% and 82%, respectively [8,19,25-27,33-36]. The
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analysis, Soriano et al [19] found that accuracy for tumor resect-
ability was maximized and costs were minimized when CT or EUS
was performed initially followed by the other tests in those with
potentially resectable neoplasms. Ahmad et al [33] proposed that
although EUS and MRI individually are not sensitive for tumor
resectability, their combined use may increase positive predictive
value of resectability compared to either test alone. When surgery
is performed only when MDCT and EUS agree on tumor resect-
ability, DeWitt et al [8] reported a nonsignificant trend toward
improved accuracy of resectability compared to either study alone.
However, a study by Bao et al [37] found that MDCT was a better
predictor of resectability than EUS. In the recent years, higher
resolution assessment for vascular invasion and distant metastasis
by multiphasic CT has assumed a larger role than EUS in determin-
ing surgical candidacy of patients with pancreatic cancer.319
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3552.6. EUS-guided tissue acquisition of pancreatic cancer
EUS-FNA remains the first-line modality for tissue sampling in
patients with pancreatic masses [38,39]. Based on the results of
2 meta-analyses [40,41], the pooled sensitivity and specificity of
EUS-FNA for diagnosis of pancreatic adenocarcinoma ranged
between 85%-89% and 96%-98%, respectively. The presence of
chronic pancreatitis may impair the visualization of tumors endo-
sonographically or hinder the cytologic interpretation of the
sampled pancreatic tissue, thus reducing sensitivity. In a series of
207 consecutive patients with focal pancreatic lesions, Fritscher-
Ravens et al [42] found that the sensitivity of EUS-FNA for the
diagnosis of malignancy in patients with normal parenchyma to be
superior (89%) to those with parenchymal evidence of chronic
pancreatitis (54%).
Today, EUS-TA by FNA (EUS-FNA) and fine-needle biopsy plays
a pivotal role in the diagnosis of pancreatic masses. Obtaining an
adequate sample and reaching an accurate diagnosis are funda-
mental endpoints of EUS-TA [39]. This is of particular importance
since many patients with malignancy are often subjected to
neoadjuvant systemic therapy prior to surgery nowadays, where
a tissue diagnosis is essential to move this process forward.
Significant efforts have been made in recent years to identify the
ideal EUS-TA technique, one that is efficient, effective, and asso-
ciated with high diagnostic yield, specimen adequacy, accuracy,
and low adverse event rate [43]. These efforts have focused on
studying several variables associated with EUS-TA outcomes and
can be categorized as: (1) those related to sampling methods and
techniques (use of suction and stylet, fanning and capillary
technique, number of passes, methods of sample expression);
(2) availability of rapid on-site evaluation (ROSE), (3) endosonog-
rapher and cytopathologist qualifications (experience, training,
and competency); and (4) type of specimen and needle used. We
will expand on each one of these variables in the subsequent
sections of this review.T1
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3682.6.1. Sampling methods and techniques
2.6.1.1. Use of suction vs capillary suction technique. Use of air
vacuum (suction) remains widely practiced during FNA of a
variety of solid and cystic lesions. Suction is generally
recommended for pancreatic solid lesions, particularly PDACs
which can carry a variable degree of stromal fibrosis and
desmoplasia. In highly vascular lesions such as lymph nodes and
neuroendocrine tumors, a nonsuction technique is recommended
allowing for a better quality and less bloody sample. Avoiding
suction in vascular lesions can improve the quality of ROSE with
less blood that could interfere with tumor visualization; however,in passes dedicated solely for cell block, suction may be
reintroduced to improve tissue acquisition.
The wet suction technique (WEST) relies on preflushing the
needle with saline to replace the column of air with fluid followed
by applying negative pressure on the proximal end of the needle.
In a prospective, single-blind, randomized, controlled trial using a
22-gauge needle for EUS-FNA of solid lesions, WEST resulted in
significantly better cellularity and specimen adequacy in cell
blocks of EUS-guided FNA aspirate of solid lesions than the
conventional FNA technique [44]. A new modified WEST (hybrid
suction technique) relies on preloading the needle with saline, but
having continuous negative pressure with a prevacuum syringe to
avoid manual intermittent suction. Data about this technique is
limited to a single-center pilot study by Berzosa et al [45]. Another
recent randomized controlled trial showed that high negative
pressure suction (generated by using a 60-mL syringe) was
associated with superior diagnostic yield compared to standard
negative pressure using a 10-mL syringe in patients with pancre-
atic masses undergoing EUS-FNA [46]. In our practice, we continue
to use suction during aspiration of solid pancreatic masses when
collecting for cell block but would limit its use when the on-site
review from the initial pass indicates large amounts of blood and
paucity of tumor cells.
Capillary suction technique utilizes capillary aspiration created
by slow and staggered withdrawal of the stylet. This has been
suggested in limited studies to enhance quality of the specimen
obtained for diagnostic purposes [47,48]. Based on 1 study, this
technique was associated with better cellular quality and diag-
nostic yield in pancreatic and liver masses [49].
2.6.1.2. Use of stylet. The presence of a stylet should prevent
the introduction of gastrointestinal wall tissue to the needle
as it traverses this to access the target lesion. However, current
data suggest that the use of a stylet does not confer any
advantage during EUS-FNA [50]. Furthermore, the use of stylet is
considered to be labor intensive and time consuming (particularly
with 25 G needles), which could prolong procedure time and
theoretically increase the risk of inadvertent needle injuries in
the endoscopy suite.
2.6.1.3. Needle size. Current EUS-FNA needles are available in 25-
gauge, 22-gauge, and 19-gauge needles. Needle size is probably
the most widely studied factor as a predictor of cytologic adequacy
and diagnostic yield of malignancy. The 22-gauge needle were
considered the default needle for a long time but a recent
reduction in its utilization has been described in favor of 25-
gauge needles, particularly when sampling pancreatic head and
uncinate process lesions. To date, 3 meta-analysis compared the
diagnostic accuracy of EUS-FNA for pancreatic masses by using 22-
and 25-gauge needles demonstrated superior sensitivity of 25-
gauge needles for diagnosing pancreatic malignancy [51-53]. In
addition, randomized controlled trials suggest that there is no
incremental diagnostic yield of 19 G vs 22 or 25 G with overall
similar safety profile [54,55]. Table 1 summarizes the studies
comparing the diagnostic yield of malignancy between 22 G and
25 G needles during EUS-FNA of pancreatic masses [56-61].
2.6.1.4. Fanning technique. The fanning technique for EUS-FNA
involves sampling multiple areas within a lesion by changing the
angle of the tip of the scope or (when smaller gauge needles are
used) by using the elevator. Bang et al [62] compared this
technique to the standard technique for EUS-FNA of solid
pancreatic mass lesions, and found fanning to be superior by
establishing a diagnosis in fewer passes, and resulted in higher
first pass diagnostic rate (86% vs 58%; P ¼ 0.02). While further data
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Table 1
Q 3 Summary of studies comparing diagnostic yield of malignancy between 22-gauge and 25-gauge needles during EUS-FNA of pancreatic masses.
Author Study design No. of patients 22G/25G Sensitivity (95% CI) 22G Sensitivity (95% CI) 25G
Siddiqui et al [56] RCT 64/67 0.88 (0.77-0.94) 0.96 (0.87-0.99)
Yusuf et al [57] Retrospective 540/302 0.84 (0.80-0.88) 0.92 (0.87-0.99)
Siddiqui et al [58] Retrospective 26/17 0.85 (0.62-0.97) 0.91 (0.59-1.00)
Camellini et al [59] RCT 43/41 0.86 (0.70-0.95) 0.89 (0.75-0.97)
Uehara e al [60] Retrospective 54/66 0.88 (0.74-0.96) 1.00 (0.91-1.00)
Fabbri e al [61] Prospective 50/50 0.85 (0.71-0.94) 0.94 (0.82-0.99)
Abbreviations: G, gauge; RCT, randomized controlled trial.
(Adapted with permission from Wani et al [39]).
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pancreatic lesions.450
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4852.6.2. Rapid on-site evaluation
The availability of a cytopathologist on site (for ROSE) has been
shown to improve the diagnostic yield of EUS-FNA for malignancy.
Prior studies demonstrated a 10%-15% increase in diagnostic yield
in the presence of ROSE and 20% rate of nondiagnostic aspirates in
its absence [70,71]. The beneficial role of ROSE for EUS-FNA of solid
pancreatic masses was confirmed by a meta-analysis of 34 studies
(3644 patients) [70]. However, recent data from 2 multicenter
trials showed no significant difference in the diagnostic yield of
malignancy, proportion of inadequate specimens, and accuracy in
patients with pancreatic mass undergoing EUS-FNA with or with-
out ROSE [71,72]. In these studies, ROSE was associated with fewer
number of passes. It has been suggested that ROSE may have a role
only during the learning phase of EUS-FNA in recently established
EUS services. In our practice, we find ROSE to be of significance in
limiting the number of passes and hence improve procedural
efficiency and reduce patient risk. It also allows a real-time
decision to be made on whether additional tissue assays are
needed (such as microbiology studies, flow cytometry, and molec-
ular assays). In the absence of ROSE, it is recommended perform-
ing 4-5 passes in solid pancreatic lesions and 2-3 passes in lymph
nodes, liver, and adrenal lesions.
The interobserver variability among cytopathologists with
regard to EUS-FNA and fine-needle biopsy specimens is an issue
that has significant implications for patient management. In a pilot
study, Mounzer et al [73] evaluated the interobserver variability
among 4 cytopathologists in assessing EUS-FNA cytology speci-
mens of solid pancreatic lesions using a novel standardized scoring
system. The study demonstrated that the interobserver agreement
for the final diagnosis was moderate (κ ¼ 0.45) with minimal
improvement when combining suspicious and malignant diagno-
ses (κ ¼ 0.54). Similar to recent advances in EUS performance
secondary to improved training and better competence and quality
metrics assessment [74], cytopathologists need to address these
critical issues in cytology performance in future studies.Table 2
Summary of studies that assessed the Procore needle for EUS-FNB compared to FNA wh
Author Study design No. of patients Needle g
Bang et al [63] RCT 28 22
Larghi et al [64] Prospective cohort 61 22
Iwashita et al [65] Retrospective 38 25
Vanbiervliet et al [66] RCT 80 22
Strand et al [67] Prospective cohort 32 22
Choi et al [68] Retrospective 80 22
Singh et al [69] Retrospective 40 22
Abbreviations: DY, diagnostic yield; FNB, Fine needle biopsy; RCT, randomized controlle
(Adapted with permission from Wani et al [39]).2.6.3. Type of specimen
EUS-FNA remains the standard procedure for sampling of
pancreatic masses. However, EUS-FNA has certain limitations.
First, primary pancreatic lymphomas (PPLs) and well-differenti-
ated ductal adenocarcinomas are often difficult to diagnose by use
of cytology alone. Second, chronic pancreatitis, if present, can
obscure the detection of pancreatic tumors and hinder a cytolog-
ical diagnosis of malignancy. Third, the low negative predictive
value of EUS-FNA does not permit exclusion of malignancy in
negative specimens. To address these limitations, core biopsy
devices have been developed to obtain histologic tissue samples
using a standard linear array echoendoscope. Two such devices
introduced over the last decade include the Quick-Core and
ProCore biopsy needles (Cook Medical, Bloomington, IN). In a
multicenter cohort study of 109 patients with intestinal and
extraintestinal lesions (including 47 pancreatic tumors), the Pro-
Core needle provided adequate histology and a correct diagnosis in
96% and 89% of cases, respectively [75]. However, in a recent meta-
analysis including 9 studies of 576 patients, there was no differ-
ence in diagnostic adequacy (75% vs 89%), diagnostic accuracy (86%
vs 86%), or rate of histologic core specimen acquisition (78% vs
77%) between the ProCore and standard FNA needles, respectively.
The mean number of passes required for diagnosis, however, was
significantly lower when using the ProCore needle (standardized
mean difference - 1.2, P o 0.001) [76]. Table 2 summarizes the
various published studies comparing the ProCore needle to stand-
ard FNA needles. Nevertheless, core biopsy needles will continue
serving niche applications such as aiding the diagnosis of auto-
immune pancreatitis (Figure 3) [77] and pancreatic lymphoma
[78], where its superiority has been demonstrated in previous
studies. In addition, core biopsy needles could be used as a rescue
technique when on-site FNA results are inconclusive or if this
service is not available (Video 2; Figure 4) [75].2.6.4. Ancillary studies
In an attempt to increase the sensitivity of EUS-FNA to detect
malignancy in pancreatic masses, investigators have evaluated
the presence of certain genetic mutations. A meta-analysis of486
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en comparative data is available.
auge FNB SA FNB (%) DY FNB (%) DY FNA (%) P value
89 80 67 0.66
89 89 n/a n/a
n/a 86/96 n/a n/a
n/a 84 88 NS
n/a 28 93 o0.001
n/a 90 62 o0.005
n/a 100 93 NS
d trial; SA, specimen adequacy.
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Fig. 3. (A) A 78-year-old man presenting with painless jaundice was found to have diffuse enlargement of the pancreas on CT and confirmed on EUS. Fine needle biopsy was
performed from the neck area using a core biopsy device. (B) A photomicrograph of a core biopsy obtained in the patient in 3A demonstrating dense lymphoplasmacytic
infiltration in the stroma. This was confirmed with plasma cells staining positive for IgG4 stains (not shown) (H&E stain ×40). H&E, hematoxylin and eosin stain. (Color
version of figure is available online.)
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analysis on EUS-FNA specimens reported a pooled sensitivity and
specificity of 77% and 93%, respectively [79]. When combined with
EUS-FNA alone, the addition of k-ras mutation testing increased
sensitivity from 81%-89% but reduced specificity from 97%-92%.
Fluorescence in situ hybridization (FISH) processing of EUS-
guided FNA specimens are other assays that were found to increase
the sensitivity and accuracy of routine cytology examination [80].
Furthermore, Kubiliun et al [81] showed that in patients with
suspected pancreatic cancer, FISH analysis can detect additional cases
missed by cytology without compromising specificity. Authors rec-
ommended EUS-FNAwith rescue FISH for the diagnosis of pancreatic
carcinoma in patients with inconclusive on-site cytopathology
results. Finally, combining routine cytology with FISH and KRAS
analyses improves diagnostic yield of EUS-FNA of solid pancreatic
masses, according to Reicher et al [82]. Such assays can be included to
further investigate atypical cytology from pancreatic EUS-FNA.
It should be noted though that KRAS mutations can be present in
the setting of chronic pancreatitis and could lead to false positive
results in 410% of cases, however, the specificity of FISH in this
setting remains high exceeding 95% [82]. To overcome such limi-
tations, differential miRNA expression in tissue specimens has been
explored as an adjunct to cytopathology for the diagnosis and
prognostication of individuals with pancreatic cancer [83,84]. A
study measuring miR-10b expression in EUS-FNA tissue samples
revealed an association between decreased miR-10b expression
in pancreas cancer cells with improved survival, response to614
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619
620
621
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Fig. 4. (H&E ×200) A patient with pancreatic head mass and previously inconclusive
EUS-FNA. Fine needle biopsy confirmed pancreatic adenocarcinoma. Rare malignant cells
can be seen in a fibrous stroma (arrows). (Color version of figure is available online.)neoadjuvant radiochemotherapy, and delayed time to metastasis
[83]. Brand et al [85] developed and validated a 5-miRNA panel
derived from EUS samples that were prospectively collected at
multiple centers. This 5-miRNA panel can accurately predict which
preoperative pancreatic EUS-FNA specimens contain PDAC. This test
might aid in the diagnosis of pancreatic cancer by reducing the
number of FNAs without a definitive adenocarcinoma diagnosis,
thereby reducing the number of repeat EUS-FNA procedures, which
could reduce procedure complications and the need for multiple
needles, and provide faster times to complete EUS-FNA. As the list
of known microRNAs involved in pancreatic cancer pathogenesis
continues to expand, we expect the utilization of such assay to grow
over the next decade and become commercially available.
2.7. Safety of EUS and EUS-FNA
EUS is a safe procedure with a reported overall adverse event
rate of 1.1%-3% [86].
Two major possible adverse events of EUS-FNA of solid pan-
creatic masses include acute pancreatitis and the risk of needle 
tract seeding. The reported risk of acute pancreatitis after EUS-FNA
of solid pancreatic masses is 0.26%-0.85% [87-89]. This risk can be
decreased by minimizing the number of needle passes, minimizing
the amount of normal appearing pancreatic parenchyma traversed
with each pass, and avoiding needle insertion through the pan-
creatic duct unless it is absolutely necessary. Needle tract seeding
is a consideration with biopsy of pancreatic masses, but most of
the published data are limited to case reports [90]. The reported
incidence of needle tract seeding after EUS-FNA is believed to be
lower than percutaneous CT or transabdominal ultrasound-guided
sampling (2.2% vs 16.3%) [91]. The majority of the reported cases of
EUS-FNA needle tract seeding are for body and tail cancers, which
were sampled through the gastric wall [90]. Needle tract seeding is
of less significance in resectable pancreatic head tumors sampled
transduodenally, because the site of needle puncture is included
within the resection margins of a pancreatoduodenectomy.623
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6323. Pancreatic neuroendocrine tumors
The use of EUS-FNA permits tissue confirmation of a suspected
pancreatic neuroendocrine tumors (PNET) [92,93]. Data from a
large retrospective case series of 80 patients, suggested that EUS
should be included in the diagnostic workup of all patients with
suspected PNETs, even when the CT study was negative for a
primary lesion in the pancreas.
F5
F6
F7
F8
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
Fig. 5. A small mass in the pancreatic head in a patient with MEN1 noted on EUS
screening examination. This lesion was not seen on CT scan but was confirmed to
be PNET on FNA. MEN1, multiple neuroendocrine neoplasia type 1.
Fig. 7. Immunostains from a PNET aspirate staining positive for chromogranin
(golden brown color) (H&E ×200). H&E, hematoxylin and eosin stain. (Color version Q12
of figure is available online.)
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diagnosis of PNETs [94-96]. Characteristic EUS findings are helpful
for the diagnosis and grading of PNETs (Figure 5) [94,95]. However,
location of the tumor in the pancreatic head and presence of rich
stromal fibrosis can negatively impact sampling adequacy [96].
Purely cystic and mixed solid-cystic PNETs have distinct clinical
and EUS characteristics, and are associated with less aggressive
biological behavior compared with solid PNETs. EUS-FNA is accu-
rate for determining malignant potential on preoperative evalua-
tion. Despite complete resection, recurrence is observed up to
5 years following surgery [97]. Cytology is usually diagnostic in
PNETs (Figure. 6), which typically stains positively for chromogra-
nin and synaptophysin (Figure 7). Recently, molecular assays
allowed genetic mutations to be reliably assessed on FNA speci-
mens from PNETs. A recent study of 29 patients with PNETs
followed for an average of 33 months showed that the presence
of allelic microsatellite loss was associated with increased PNET
recurrence, progression, and mortality [98].740
741
742
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7454. Primary pancreatic lymphoma
EUS-FNA with flow cytometry is very accurate for PPL. In a case
series of 16 patients with PPL, Khashab et al [99] reported aFig. 6. FNA from a PNET demonstrating classic cytopathologic findings including
predominantly small loosely cohesive groups of cells that are small to medium in
size with a uniform round to oval, and often peripherally located nuclei. (H&E stain
×100). H&E, hematoxylin and eosin stain. (Color version of figure is available
online.)sensitivity and specificity of EUS-FNA with cytology and flow
cytometry of 84.6% and 100%, respectively. This is in contrast to
EUS-FNA with cytology alone, which had sensitivity and specificity
less than 30%. This diagnosis should be suspected based on clinical
appearance, lack of definite malignancy, and abundance of abnor-
mal lymphocytes on rapid cytological review.5. Pancreatic metastases
EUS-FNA permits an accurate cytologic diagnosis of metastatic
lesions to the pancreas. In the largest series to date of 72 masses in
49 patients, El Hajj et al [100] reported metastatic lesions from
kidney (renal cell carcinoma in 21), lung (n ¼ 8), skin (n ¼ 6), colon
(n ¼ 4), breast (n ¼ 3), small bowel (n ¼ 2), stomach (n ¼ 2), liver
(n ¼ 1), ovary (n ¼ 1), and bladder (n ¼ 1). Metastasis to the
pancreas may occur many years (especially for renal cell carcinoma;
Figure 8) after diagnosis of the primary tumor. Obtaining a detailed
medical history for previous malignancy may raise suspicion for this
diagnosis. In patients with a remote history of malignancy, obtain-
ing additional cytological material for cell block and the use of
immunocytochemistry may be helpful to confirm the diagnosis of
pancreatic metastases and confirm recurrent malignancy.746
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Fig. 8. A patient with known history of renal cell carcinoma treated 15 years earlier
presented with painless jaundice. A pancreatic head lesion was found on EUS,
confirmed on FNA to be renal cell carcinoma.
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Supplementary data associated with this article can be found in
the online version at http://dx.doi.org/10.1016/j.tgie.2018.01.002.
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